Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial
Mené entre 2016 et 2020 sur 282 femmes à haut risque de cancer du sein (âge moyen : 57 ans), cet essai randomisé évalue l'efficacité, du point de vue de l'adhésion à un traitement chimiopréventif à 6 mois, d'un outil en ligne d'aide à la décision mis à disposition des professionnels de santé
Significant under-utilization of breast cancer chemoprevention remains, despite guidelines stating that physicians should recommend chemoprevention with anti-estrogen therapy to high-risk women. We randomized women, age 35-75 years, who met high-risk criteria for breast cancer, without a personal history of breast cancer or prior chemoprevention use, to standard educational materials alone or combined with a web-based decision aid. All healthcare providers, including primary care providers and breast specialists, were given access to a web-based decision support tool. The primary endpoint was chemoprevention uptake at 6 months. Secondary outcomes included decision antecedents (perceived breast cancer risk/worry, chemoprevention knowledge, self-efficacy) and decision quality (decision conflict, chemoprevention informed choice) based upon patient surveys administered at baseline, 1 and 6 months after randomization. Among 282 evaluable high-risk women enrolled from November 2016 to March 2020, mean age was 57 years (SD, 9.9) and mean 5-year invasive breast cancer risk was 2.98% (SD, 1.42). There was no significant difference in chemoprevention uptake at 6 months between the intervention and control groups (2.1% vs. 3.5%). Comparing the intervention and control arms at 1 month, there were significant differences among high-risk women in accurate breast cancer risk perceptions (56% vs. 39%, p=0.017), adequate chemoprevention knowledge (49% vs. 27%, p<0.001), mean decision conflict (34.0 vs. 47.0, p<0.001), and informed choice (41% vs. 23%, p=0.003). These differences were no longer significant at 6 months. Although our decision support tools did not result in a significant increase in chemoprevention uptake, we did observe improvements in decision antecedents and decision quality measures.